May 3 (Reuters) - Novavax Inc said on Monday it had expanded the late-stage study testing its COVID-19 vaccine candidate to include up to 3,000 adolescents aged 12 to 17. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Our Standards: The Thomson Reuters Trust Principles.